This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Dinoprostone concentrate for solution for infusion 10mg/ml


Infusions of dinoprostone.

Drugs List

  • dinoprostone 5mg/0.5ml concentrate for solution for infusion
  • PROSTIN E2 5mg/0.5ml concentrate for solution for infusion
  • Therapeutic Indications


    Oxytocic for therapeutic termination of pregnancy
    Therapeutic termination of pregnancy in hydatidiform mole
    Therapeutic termination of pregnancy in missed abortion

    Unlicensed Uses

    Maintenance of patency of ductus arteriosus (before corrective surgery)



    Initially: Prepare a sterile solution of dinoprostone in normal saline or 5% dextrose containing 5 micrograms per ml and infuse at 2.5 micrograms per minute for 30 minutes.

    If a satisfactory uterine contractility response is produced, maintain infusion rate of 2.5 micrograms per minute. In unsatisfactory uterine contractility response, increase infusion rate to 5 micrograms per minute. If satisfactory uterine activity is not produced after at least 4 hours the rate may be increased to 10 micrograms per minute, maintaining until abortion occurs or the treatment is considered a failure. If significant side effects occur, the rate of infusion should be decreased by 50% or discontinued.

    If a constant rate infusion pump is used, a different concentration of solution (e.g 15 micrograms/per ml) may be required, dependent on the type of pump, but the dose rates (micrograms/per minute) should remain the same.

    Continuous administration for more than 2 days is not recommended.

    Additional Dosage Information

    Recommencing treatment after hypertonic uterus should be started at 50% of the last dose level used.


    For intravenous infusion only.


    Previous Caesarean section
    Cardiac disorder
    Cephalopelvic disproportion
    Foetal malpresentation
    Hepatic disorder
    History of pelvic inflammatory disease
    History of uterine surgery
    Pulmonary disease
    Renal disorder
    Uncontrolled pelvic inflammatory disease
    Uterine hypertonia

    Precautions and Warnings

    Risk factors for disseminated intravascular coagulation
    Epileptic disorder
    History of asthma
    History of seizures
    Raised intra-ocular pressure
    Scarred uterus

    Failed/incomplete abortion - therapy for complete evacuation must be given
    Treatment to be prescribed under the supervision of a specialist
    Contains alcohol
    Avoid contact of product with skin
    Must be diluted before use; see product information
    Pregnancy: Monitor for disseminated intravascular coagulation postpartum
    Discontinue & re-assess patient if uterine hypertonia occurs

    Women aged 35 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have been shown to have an increased risk of post-partum disseminated intravascular coagulation. In addition, these factors may further increase the risk associated with labour induction. Therefore, in these women, use of dinoprostone should be undertaken with caution. Measures should be applied to detect as soon as possible an evolving fibrinolysis in the immediate post-partum phase.

    Dinoprostone should not be administered by the intramyometrial route as there is a possible association between this route and cardiac arrest in severely ill patients.

    Pregnancy and Lactation


    Dinoprostone infusion is used for termination of pregnancy, missed abortion and hydatidiform mole.

    Animal studies have shown teratogenic effects. If abortion does not occur or is suspected to be incomplete as a result of prostaglandin therapy (as in spontaneous abortion, where the process is sometimes incomplete), the appropriate treatment for complete evacuation of the pregnant uterus should be instituted in all instances.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Dinoprostone infusion is excreted in breast milk. This is not expected to be harmful due to the nature in which the product is used.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abruptio placentae
    Amniotic fluid embolism
    Anaphylactic shock
    Back pain
    Cardiac arrest
    Erythema at injection site
    Hypersensitivity reactions
    Intravascular coagulation (disseminated)
    Irritation (localised)
    Local infection
    Pyrexia (temporary)
    Rapid cervical dilation
    Uterine hypertonus
    Uterine rupture
    White blood cell count raised


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2018

    Reference Sources

    Summary of Product Characteristics: Prostin E2 Sterile solution 10mg/ml. Pharmacia Ltd. Revised January 2018.

    NICE Evidence Services Available at: Last accessed: 11 September 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.